Showing results (41-50 of 223) with videos related to

Sort By:
Pageof 23
Targeted Oncology|November 19, 2020
Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation TrialCéleste Lebbé, Antoine Italiano, Nadine Houédé, et al.
Cancer|September 2, 2020
Phase 1 study of the immunotoxin LMB-100 in patients with mesothelioma and other solid tumors expressing mesothelinRaffit Hassan, Christine Alewine, Idrees Mian, et al.
British Journal of Cancer|August 26, 2020
A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics and pharmacodynamics of AsiDNA, a first-in-class DNA repair inhibitor, administered intravenously in patients with advanced solid tumoursChristophe Le Tourneau, Jean-Pierre Delord, Nuria Kotecki, et al.
Frontiers in Oncology|May 10, 2021
Radiotherapy in the Era of Immunotherapy With a Focus on Non-Small-Cell Lung Cancer: Time to Revisit Ancient Dogmas?Jonathan Khalifa, Julien Mazieres, Carlos Gomez-Roca, et al.
European Journal of Cancer (Oxford, England : 1990)|October 23, 2017
First-in-man phase I study assessing the safety and pharmacokinetics of a 1-hour intravenous infusion of the doxorubicin prodrug DTS-201 every 3 weeks in patients with advanced or metastatic solid tumoursPatrick Schöffski, Jean-Pierre Delord, Etienne Brain, et al.
Bulletin Du Cancer|April 6, 2013
[The management of the metastatic disease by the surgeons]Eliane Mery, Muriel Golzio, Benoît Thibault, et al.
Therapie|July 27, 2013
Drugs and cancer: an analysis of the French Pharmacovigilance DatabaseGeneviève Durrieu, Benjamin Mazau, Jérémi Jégu, et al.
Skin Appendage Disorders|February 25, 2017
Development of Photoonycholysis with Vandetanib TherapyMiruna Negulescu, Slimane Zerdoud, Serge Boulinguez, et al.
British Journal of Cancer|July 3, 2026
The concept of functional cure in advanced/metastatic melanoma treated with combined nivolumab and ipilimumab or nivolumab aloneAna Cavillon, Isabelle Borget, Caroline Robert, et al.
Science Translational Medicine|January 24, 2024
The CSF-1R inhibitor pexidartinib affects FLT3-dependent DC differentiation and may antagonize durvalumab effect in patients with advanced cancersAurélien Voissière, Carlos Gomez-Roca, Sylvie Chabaud, et al.
Pageof 23